Were Patrick John Finn’s Twist Bioscience (TWST) share sales under a Rule 10b5-1 plan?

Yes. The Form 4 states the transactions were executed pursuant to a Rule 10b5-1 trading plan. This plan was previously adopted by Patrick John Finn on May 13, 2025, providing a pre-arranged framework for selling shares over time.

Twist Bioscience (TWST) COO sells 68,967 shares under 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Twist Bioscience Corp President and COO Patrick John Finn reported multiple transactions in the company’s stock. On February 17, 2026, he exercised two stock options covering 32,300 and 18,205 shares of common stock.

On the same date, he sold a total of 68,967 shares of common stock in open-market transactions at weighted average prices of $50.321, $51.423, $52.686 and $53.110 per share under a pre-established Rule 10b5-1 trading plan adopted on May 13, 2025. After these transactions, he directly owned 287,788 shares of Twist Bioscience common stock.

Insider Trade Summary

Net Seller: 68,967 shares ($3,562,417)

Net Sell 8 txns

Insider Finn Patrick John

Role President and COO

Sold 68,967 shs ($3.56M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	32,300	$0.00	--
Exercise	Stock Option (right to buy)	18,205	$0.00	--
Exercise	Common Stock	18,205	$23.33	$425K
Exercise	Common Stock	32,300	$26.66	$861K
Sale	Common Stock	21,858	$50.321	$1.10M
Sale	Common Stock	16,616	$51.423	$854K
Sale	Common Stock	26,952	$52.686	$1.42M
Sale	Common Stock	3,541	$53.11	$188K

Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct); Common Stock — 324,455 shares (Direct)

Footnotes (1)

The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. Represents the weighted average sales price per share. The shares sold at prices ranging from $50.00 to $50.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. The shares sold at prices ranging from $51.00 to $51.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. The shares sold at prices ranging from $52.00 to $52.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. The shares sold at prices ranging from $53.01 to $53.25 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. The option is immediately exercisable. 12/60th of the shares subject to the option vest and become exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. The option is immediately exercisable. 25% of the shares subject to the option vest and become exercisable on October 24, 2020 and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuing service through each vesting date.

Form 4 Insider Transactions: What Each Field Means →

02/19/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Finn Patrick John

(Last)

(First)

(Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/17/2026		M⁽¹⁾		18,205	A	$23.33	324,455	D
Common Stock	02/17/2026		M⁽¹⁾		32,300	A	$26.66	356,755	D
Common Stock	02/17/2026		S⁽¹⁾		21,858⁽²⁾	D	$50.321	334,897	D
Common Stock	02/17/2026		S⁽¹⁾		16,616⁽³⁾	D	$51.423	318,281	D
Common Stock	02/17/2026		S⁽¹⁾		26,952⁽⁴⁾	D	$52.686	291,329	D
Common Stock	02/17/2026		S⁽¹⁾		3,541⁽⁵⁾	D	$53.11	287,788	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$26.66	02/17/2026		M⁽¹⁾			32,300	⁽⁶⁾	11/18/2028	Common Stock	32,300	$0	0	D
Stock Option (right to buy)	$23.33	02/17/2026		M⁽¹⁾			18,205	⁽⁷⁾	10/23/2029	Common Stock	18,205	$0	0	D

Explanation of Responses:

1. The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025.

2. Represents the weighted average sales price per share. The shares sold at prices ranging from $50.00 to $50.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

3. Represents the weighted average sales price per share. The shares sold at prices ranging from $51.00 to $51.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

4. Represents the weighted average sales price per share. The shares sold at prices ranging from $52.00 to $52.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

5. Represents the weighted average sales price per share. The shares sold at prices ranging from $53.01 to $53.25 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

6. The option is immediately exercisable. 12/60th of the shares subject to the option vest and become exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

7. The option is immediately exercisable. 25% of the shares subject to the option vest and become exercisable on October 24, 2020 and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuing service through each vesting date.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Patrick John Finn	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Patrick John Finn report for Twist Bioscience (TWST)?

Patrick John Finn, President and COO of Twist Bioscience, reported exercising two stock options and selling common shares on February 17, 2026. He converted options into common stock and then executed multiple open-market sales under a pre-established Rule 10b5-1 trading plan.

How many Twist Bioscience (TWST) shares did Patrick John Finn sell and at what prices?

Patrick John Finn sold a total of 68,967 Twist Bioscience common shares in several open-market trades. The weighted average sale prices were $50.321, $51.423, $52.686, and $53.110 per share, with detailed price breakdowns available upon request from the company or regulators.

How many Twist Bioscience (TWST) shares does Patrick John Finn own after these transactions?

Following the reported option exercises and stock sales, Patrick John Finn directly owns 287,788 shares of Twist Bioscience common stock. This figure reflects his direct holdings immediately after the February 17, 2026 transactions disclosed in the Form 4 filing.

What stock options did Patrick John Finn exercise in the latest Twist Bioscience (TWST) Form 4?

He exercised two stock options, each described as a “Stock Option (right to buy).” The exercises covered 32,300 shares and 18,205 shares, respectively, which were immediately exercisable under previously granted option agreements with specified vesting schedules.

What is the nature of the stock sales reported by Patrick John Finn at Twist Bioscience (TWST)?

The reported stock sales are classified as open-market or private transactions, coded as “S” on Form 4. They represent routine disposition of common shares at market-based prices, executed under a Rule 10b5-1 trading plan previously established by the executive.